CA2261887A1 - Conjugues lipidiques polaires covalents associes a des composes biologiquement actifs utilisables dans les onguents - Google Patents

Conjugues lipidiques polaires covalents associes a des composes biologiquement actifs utilisables dans les onguents

Info

Publication number
CA2261887A1
CA2261887A1 CA002261887A CA2261887A CA2261887A1 CA 2261887 A1 CA2261887 A1 CA 2261887A1 CA 002261887 A CA002261887 A CA 002261887A CA 2261887 A CA2261887 A CA 2261887A CA 2261887 A1 CA2261887 A1 CA 2261887A1
Authority
CA
Canada
Prior art keywords
salves
drug
drugs
agents
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002261887A
Other languages
English (en)
Other versions
CA2261887C (fr
Inventor
Milton B. Yatvin
Michael H. B. Stowell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health Science University
Original Assignee
Oregon Health Sciences University
Milton B. Yatvin
Michael H. B. Stowell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health Sciences University, Milton B. Yatvin, Michael H. B. Stowell filed Critical Oregon Health Sciences University
Publication of CA2261887A1 publication Critical patent/CA2261887A1/fr
Application granted granted Critical
Publication of CA2261887C publication Critical patent/CA2261887C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002261887A 1996-07-23 1996-07-23 Conjugues lipidiques polaires covalents associes a des composes biologiquement actifs utilisables dans les onguents Expired - Fee Related CA2261887C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/012124 WO1998003204A1 (fr) 1996-07-23 1996-07-23 Conjugues lipidiques polaires covalents associes a des composes biologiquement actifs utilisables dans les onguents

Publications (2)

Publication Number Publication Date
CA2261887A1 true CA2261887A1 (fr) 1998-01-29
CA2261887C CA2261887C (fr) 2007-10-02

Family

ID=22255500

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002261887A Expired - Fee Related CA2261887C (fr) 1996-07-23 1996-07-23 Conjugues lipidiques polaires covalents associes a des composes biologiquement actifs utilisables dans les onguents

Country Status (5)

Country Link
EP (1) EP0917473A1 (fr)
JP (1) JPH11514009A (fr)
AU (1) AU724421B2 (fr)
CA (1) CA2261887C (fr)
WO (1) WO1998003204A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033883A1 (fr) * 1998-12-04 2000-06-15 Oregon Health Sciences University Conjugues lipides polaires covalents avec medicaments antimicrobiens et antineoplasiques destines a cibler des sites biologiques proteges
US6464992B2 (en) * 2000-04-14 2002-10-15 University Of Kentucky Research Foundation Topical micronutrient delivery system and uses thereof
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
EA032840B8 (ru) * 2011-06-22 2020-06-18 Вайоми Терапеутикс Лимитед Пролекарства на основе конъюгатов противогрибковых агентов и их применение
WO2024083171A1 (fr) * 2022-10-20 2024-04-25 苏州艾博生物科技有限公司 Composé lipidique et composition de nanoparticules lipidiques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
JPH05507929A (ja) * 1990-06-15 1993-11-11 ウェイク　フォレスト　ユニバーシティー エーテル脂質―ヌクレオシド共有結合体
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting

Also Published As

Publication number Publication date
JPH11514009A (ja) 1999-11-30
WO1998003204A1 (fr) 1998-01-29
AU6594596A (en) 1998-02-10
EP0917473A1 (fr) 1999-05-26
AU724421B2 (en) 2000-09-21
CA2261887C (fr) 2007-10-02

Similar Documents

Publication Publication Date Title
CA2269947A1 (fr) Conjugues lipidiques, polaires et covalents utilises pour le ciblage de medicaments
US5543389A (en) Covalent polar lipid-peptide conjugates for use in salves
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
WO2003039677A3 (fr) Conjugues covalents de composes biologiquement actifs avec des acides amines et des derives d'acides amines pour le ciblage vers des sites physiologiquement proteges
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
CA2079814A1 (fr) Lipides cationiques pour la liberation intracellulaire de molecules presentant une action biologique
WO2002043652A3 (fr) Medicaments anti-proliferation
CA2184242A1 (fr) Systeme de ciblage d'un medicament, procede de preparation et utilisation de ce medicament
WO2004060384A3 (fr) Compositions pharmaceutiques de toxine botulique amelioree
WO2006086631A3 (fr) Procedes de mise en oeuvre d'une therapie par irradiation par microfaisceaux
WO2005084710A3 (fr) Systeme d'administration de medicaments par nanocellules
RU93058654A (ru) Способ определения полезности пролекарств, превращающихся печенью, их применение в терапии, пролекарство
EP2186902A3 (fr) Mise à l'échelle de polarisation de couple d'un côté sur l'autre afin d'améliorer la dérive dans une transmission à quatre roues motrices programmable
EP0858996A4 (fr) Agents de protection des cellules nerveuses
WO2006068759A3 (fr) Liposomes contenant des agents phytochimique et methodes de fabrication et d'utilisation desdits agents
WO2001026704A3 (fr) Activation ciblee d'un medicament
WO2000018316A3 (fr) Composition ophtalmique agreable, a liberation prolongee, et procede de therapie oculaire
WO2003072030A3 (fr) Procedes de prevention ou de traitement de l'arythmie cardiaque
GR3026602T3 (en) Morphogen-induced liver regeneration.
CA2317582A1 (fr) Forme posologique de medicament reposant sur le gradient de teorell-meyer
WO2002102311A3 (fr) Compositions pharmaceutique et de diagnostic contenant des nanoparticules utiles pour le traitement de tissus et de cellules cibles
CA2261887A1 (fr) Conjugues lipidiques polaires covalents associes a des composes biologiquement actifs utilisables dans les onguents
WO2002026245A3 (fr) Methodes de traitement de reactions inflammatoires et immunitaires et compositions associees
PL1689404T3 (pl) Połączenie ET-743 z pro lekami 5-fluorouracylu do leczenia raka
HU229598B1 (en) Preparations for the application of anti-inflammatory agents

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed